Royal Bank of Canada’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$109M Sell
174,515
-176,656
-50% -$120M 0.02% 670
2026
Q1
$271M Buy
351,171
+5,952
+2% +$4.56M 0.05% 339
2025
Q4
$266M Sell
345,219
-27,876
-7% -$18.9M 0.04% 345
2025
Q3
$210M Sell
373,095
-11,784
-3% -$6.66M 0.03% 414
2025
Q2
$202M Buy
384,879
+181,682
+89% +$101M 0.04% 395
2025
Q1
$129M Sell
203,197
-85,740
-30% -$59M 0.03% 460
2024
Q4
$206M Buy
288,937
+27,497
+11% +$23.1M 0.04% 353
2024
Q3
$275M Buy
261,440
+62,494
+31% +$69.5M 0.06% 291
2024
Q2
$209M Buy
198,946
+60,392
+44% +$58.5M 0.05% 316
2024
Q1
$133M Sell
138,554
-123,237
-47% -$117M 0.03% 416
2023
Q4
$230M Buy
261,791
+101,858
+64% +$83.9M 0.05% 296
2023
Q3
$132M Buy
159,933
+6,991
+5% +$5.49M 0.04% 394
2023
Q2
$110M Sell
152,942
-27,883
-15% -$21.5M 0.03% 456
2023
Q1
$149M Sell
180,825
-117,229
-39% -$88.4M 0.04% 370
2022
Q4
$215M Sell
298,054
-25,495
-8% -$18.8M 0.06% 279
2022
Q3
$223M Sell
323,549
-13,074
-4% -$8.23M 0.07% 238
2022
Q2
$199M Buy
336,623
+22,270
+7% +$14.5M 0.06% 275
2022
Q1
$220M Buy
314,353
+36,234
+13% +$22.9M 0.05% 290
2021
Q4
$176M Buy
278,119
+81,162
+41% +$49.9M 0.04% 359
2021
Q3
$119M Buy
196,957
+96,126
+95% +$59.7M 0.03% 436
2021
Q2
$56.3M Sell
100,831
-1,125
-1% -$570K 0.02% 692
2021
Q1
$48.2M Sell
101,956
-63,374
-38% -$30.9M 0.01% 728
2020
Q4
$79.9M Buy
165,330
+44,708
+37% +$24.1M 0.02% 521
2020
Q3
$67.5M Buy
120,622
+12,415
+11% +$7.53M 0.02% 503
2020
Q2
$67.5M Buy
108,207
+25,862
+31% +$14.7M 0.03% 474
2020
Q1
$40.2M Buy
82,345
+12,107
+17% +$4.99M 0.02% 572
2019
Q4
$26.4M Sell
70,238
-31,655
-31% -$10.7M 0.01% 981
2019
Q3
$28.3M Buy
101,893
+29,932
+42% +$8.86M 0.01% 862
2019
Q2
$22.5M Sell
71,961
-54,339
-43% -$18.1M 0.01% 1011
2019
Q1
$51.9M Buy
126,300
+41,108
+48% +$16.9M 0.02% 560
2018
Q4
$31.8M Buy
85,192
+512
+0.6% +$187K 0.02% 729
2018
Q3
$34.2M Buy
84,680
+16,828
+25% +$6.4M 0.01% 794
2018
Q2
$23.4M Sell
67,852
-23,844
-26% -$7.46M 0.01% 977
2018
Q1
$31.6M Buy
91,696
+16,566
+22% +$5.76M 0.01% 802
2017
Q4
$28.2M Buy
75,130
+9,216
+14% +$3.73M 0.01% 918
2017
Q3
$29.5M Sell
65,914
-1,550
-2% -$738K 0.01% 834
2017
Q2
$33.1M Buy
67,464
+2,802
+4% +$1.23M 0.02% 743
2017
Q1
$25.1M Sell
64,662
-7,061
-10% -$2.62M 0.01% 883
2016
Q4
$26.3M Buy
71,723
+13,658
+24% +$5.19M 0.01% 872
2016
Q3
$23.3M Buy
58,065
+5,237
+10% +$2.1M 0.01% 910
2016
Q2
$18.4M Sell
52,828
-10,903
-17% -$4.2M 0.01% 1014
2016
Q1
$23M Sell
63,731
-2,817
-4% -$1.16M 0.01% 853
2015
Q4
$36.1M Buy
66,548
+14,554
+28% +$7.89M 0.02% 598
2015
Q3
$24.2M Sell
51,994
-20,259
-28% -$10.9M 0.02% 667
2015
Q2
$36.9M Sell
72,253
-631
-0.9% -$308K 0.03% 513
2015
Q1
$32.9M Sell
72,884
-19,257
-21% -$8.16M 0.02% 563
2014
Q4
$37.8M Buy
92,141
+7,885
+9% +$3.1M 0.02% 539
2014
Q3
$30.4M Buy
84,256
+45,918
+120% +$15.4M 0.02% 592
2014
Q2
$10.8M Sell
38,338
-41,061
-52% -$12.2M 0.01% 1180
2014
Q1
$23.8M Sell
79,399
-20,461
-20% -$6.3M 0.02% 666
2013
Q4
$27.5M Buy
99,860
+9,021
+10% +$2.59M 0.02% 620
2013
Q3
$28.4M Buy
90,839
+31,268
+52% +$8.22M 0.02% 553
2013
Q2
$13.4M Buy
+59,571
New +$13.9M 0.01% 881

Other funds holding REGN

Royal Bank of Canada's REGN Position: Q2 2026 in Review

Royal Bank of Canada reduced its Regeneron Pharmaceuticals (REGN) stake by 50% in Q2 2026, selling an estimated $120M and leaving 174,515 shares worth $109M. The position accounts for 0.02% of the portfolio, ranked #670.

Royal Bank of Canada first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $275M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Royal Bank of Canada held 174,515 shares of Regeneron Pharmaceuticals worth $109M as of Q2 2026.
  • Royal Bank of Canada sold 176,656 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $120M.
  • Regeneron Pharmaceuticals made up 0.02% of Royal Bank of Canada's portfolio in Q2 2026, its #670 holding.
  • Royal Bank of Canada first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's Regeneron Pharmaceuticals position peaked at $275M in Q3 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.